ResearchMoz presents professional and in-depth study of "Cognitive Impairment Disorders Drug Development Pipeline Review, 2018".
Summary
This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1743272
These disorders are associated with impairments in cognitive abilities such as learning, memory and perception. Due to the complex and highly sophisticated nature of the central nervous system (CNS), the pathophysiology of these disorders is not well understood and treatment options remain limited. Currently, marketed drugs act by slowing disease progression or treating symptoms.
Worldwide, the burden of cognitive impairment disorders will increase significantly in the coming decades due to aging populations. Consequently, there is a strong need to develop new therapies that effectively treat symptoms and target underlying mechanisms of disease.
Scope
- Which companies are the most active within the pipeline for cognitive impairment disorders?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
View Complete TOC with tables & Figures @ https://www.researchmoz.us/cognitive-impairment-disorders-drug-development-pipeline-review-2018-report.html/toc
Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 12
2.1 Cognitive Impairment Disorders Report Coverage 12
2.2 Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 12
2.3 Dementia - Overview 12
2.4 Mild Cognitive Impairment - Overview 12
2.5 Alzheimer's Disease - Overview 12
3 Therapeutics Development 13
3.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 13
3.2 Dementia 18
3.3 Mild Cognitive Impairment 30
3.4 Alzheimer's Disease 36
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1743272
4 Therapeutics Assessment 90
4.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 90
4.2 Dementia 97
4.3 Mild Cognitive Impairment 108
4.4 Alzheimer's Disease 116
5 Companies Involved in Therapeutics Development 140
5.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 140
5.2 Dementia 148
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
Summary
This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1743272
These disorders are associated with impairments in cognitive abilities such as learning, memory and perception. Due to the complex and highly sophisticated nature of the central nervous system (CNS), the pathophysiology of these disorders is not well understood and treatment options remain limited. Currently, marketed drugs act by slowing disease progression or treating symptoms.
Worldwide, the burden of cognitive impairment disorders will increase significantly in the coming decades due to aging populations. Consequently, there is a strong need to develop new therapies that effectively treat symptoms and target underlying mechanisms of disease.
Scope
- Which companies are the most active within the pipeline for cognitive impairment disorders?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
View Complete TOC with tables & Figures @ https://www.researchmoz.us/cognitive-impairment-disorders-drug-development-pipeline-review-2018-report.html/toc
Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 12
2.1 Cognitive Impairment Disorders Report Coverage 12
2.2 Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 12
2.3 Dementia - Overview 12
2.4 Mild Cognitive Impairment - Overview 12
2.5 Alzheimer's Disease - Overview 12
3 Therapeutics Development 13
3.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 13
3.2 Dementia 18
3.3 Mild Cognitive Impairment 30
3.4 Alzheimer's Disease 36
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1743272
4 Therapeutics Assessment 90
4.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 90
4.2 Dementia 97
4.3 Mild Cognitive Impairment 108
4.4 Alzheimer's Disease 116
5 Companies Involved in Therapeutics Development 140
5.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 140
5.2 Dementia 148
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
No comments:
Post a Comment